Study wrapper · #812
Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
Editor's note
This is a pharmacovigilance study of a live safety question — the reported association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition serious enough to have prompted European Medicines Agency review. Using the FDA Adverse Event Reporting System, the authors found a very strong disproportionality signal for semaglutide (355 reports; reporting odds ratio around 94) and smaller but significant signals for tirzepatide and liraglutide, while dulaglutide, exenatide and lixisenatide showed none — arguing against a uniform class effect. The central caveat is fundamental to the method: FAERS is a spontaneous-reporting database, so disproportionality signals reflect reporting patterns, not incidence, and cannot establish causation or absolute risk. Media attention and regulatory notoriety can inflate reporting for a drug like semaglutide. The authors say as much, calling for prospective, ophthalmologist-confirmed studies. Because side effects and risks belong above the fold on our peptide pages, this is worth surfacing — with disproportionality framed carefully as a hypothesis-generating signal.
Plain-language abstract
This study examined a possible eye-related safety concern with popular GLP-1 medications. A serious condition called NAION — a kind of sudden, stroke-like damage to the optic nerve — has been reported alongside semaglutide use, enough that European regulators launched a review. To compare across drugs, researchers mined the FDA's public database of adverse-event reports and used statistical methods to see which drugs had a disproportionately high number of these eye-injury reports. Semaglutide stood out with a very strong signal (355 reports), while tirzepatide and liraglutide showed smaller but real signals, and three other similar drugs showed none. Among semaglutide reports, the average age was 59, with disability recorded in 18% and hospitalization in 11%. A crucial limitation: this kind of database can only show that reports cluster around certain drugs — it cannot prove the drug caused the problem, and it cannot tell you how common the risk actually is, because reporting is voluntary and heavily publicized drugs get reported more. The authors call for rigorous follow-up studies with eye specialists confirming diagnoses.